Homepage > Company > Media > Pharma News > 2021 > Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19

Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19

A study out of Colombia investigated the effect of ivermectin on symptom duration in the setting of mild COVID-19 infection. The primary analysis included 400 adults, who were enrolled and randomized within 1 week of presenting with symptoms. It took a median 10 days for symptoms to resolve in participants who received a 5-day course of ivermectin. Symptoms went away after 12 days in participants who received placebo, for a difference that was not considered statistically significant.

By the end of day 21, the prespecified follow-up period, symptoms had resolved in 82% of individuals in the intervention group and 79% of individuals in the control group. Evidence from this single-center study does not support ivermectin for the purpose of symptom resolution in patients with mild COVID-19; however, the study authors suggest that larger trials might shine light on the drug's effect on other clinically relevant outcomes.

MARCH 8, 2021

https://www.pharmacist.com/

Read also

Spinogenix’s ALS hopeful to advance to registrational trial

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study.

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakne...

Cencora

Cencora to invest $1bn in US pharma distribution network

Celltrion

Celltrion Signs Licensing Deal with U.S. Kaigene for Two Antibody Drug Candidates